Futura Medical Regulatory News (FUM)

10 Jun 2009 07:00



Futura Medical plc

("Futura" or "the Company")

AGM Statement

Futura Medical plc (AIM: FUM), the pharmaceutical group that develops innovative products for consumer healthcare, will hold its Annual General Meeting in London later today.

At the meeting, Dr William Potter, the Company's Chairman, will make the following statement:

"The year to date has started well and we are pleased with progress across our portfolio of product opportunities. As outlined in our 2008 Annual Report, we expect marketing authorisation for CSD500 around the end of the current year with the product's launch by SSL International plc as a Durex®-branded condom thereafter.

"I am delighted to say that SSL endorsed our confidence in the commercial potential of CSD500 with a quote in our Annual Report stating: 'We are committed to launching CSD500 as soon as possible and believe it will become a leading product in the Durex® portfolio.'

"We are also in various stages of commercial discussions with marketing partners for three of our other pipeline products, TPR100, PET500 and RAD100. The latter is the most recent addition to our portfolio and has already shown promising in vitro results in the provision of local anaesthesia prior to injections.

"We look forward to updating the market in the near future on these commercial discussions, and on other progress at the Company during the remainder of the year. We view the year ahead, and beyond, with confidence."

For any further information please contact:

  Notes to Editors

Futura Medical plc

Futura Medical is a pharmaceutical group that develops innovative products for consumer healthcare. The Company is developing a portfolio of products and its strategy is to license their manufacture and distribution to major pharmaceutical and healthcare groups.

Futura is based in Guildford, Surrey, and its shares trade on the AIM market of the London Stock Exchange.

www.futuramedical.co.uk